All Sections

Home | Health

Tangled incentives push drugmakers away from an opioid solution

By JARED S. HOPKINS
Bloomberg

November 26. 2017 11:20PM




For the drug industry, building a better pain pill is a problem.

Pharmaceutical companies have introduced new medicines to treat dependence, reverse overdoses, and deal with opioids’ side effects. But few effective and economically viable alternatives to addictive painkillers have emerged from the laboratory.

That’s because of broken incentives, according to economists and industry experts. The payment policies of insurers and government health programs, along with pressure from investors, have encouraged drugmakers to treat the symptoms of the opioid epidemic but discouraged innovations that might get to the root of the problem.

New therapies for pain have generally been too expensive, too cumbersome to use, or targeted at too small a group of patients.

“There is nothing quite like a simple pain pill to solve a pain problem,” said Marvin Seppala, chief medical officer at Hazelden Betty Ford in Minnesota, which helps treat addiction.

Selling those simple pills was lucrative for years for drugmakers, wholesalers, pharmacies and other players. Opioids remain popular with doctors and the 125 million Americans who suffer from chronic pain; research firm Informa Pharma Intelligence expects sales to climb to $18.4 billion in 2020, a 25 percent increase from 2015.

Most opioids are cheap generic drugs that have been prescribed for decades, making the effort and expense of developing new painkillers hard to justify.

Drugmakers have instead invested in developing complex medicines for cancer and rare diseases, which can fetch six-figure price tags.

“Companies got out of the pain business,” said Pratap Khedkar of ZS Associates, a sales and marketing consultant who studies the pharmaceutical industry. “It’s not the hotbed of innovation.”

Pharmaceutical companies that have sought to bring new pain medications to market have mostly focused on patients with more acute needs, such as those who’ve had certain types of surgery or are suffering from conditions like arthritis.

Pfizer and Eli Lilly are developing an experimental nonopioid painkiller for osteoarthritis and chronic low back pain called tanezumab. Research was paused more than once over safety concerns, although late-stage testing is set to finish by the second half of 2018. The companies said that if approved, it would be the first in a new class of nonopioid pain drugs.

Nektar Therapeutics is developing an opioid that is designed to limit the euphoria patients feel when taking other painkillers — a major factor in driving addiction. It failed in early trial, but in March was found to have helped reduce patients’ chronic lower-back pain in a final-stage trial.

Two firms studying pain have earned highly coveted grants from the National Institute for Drug Abuse, part of the National Institutes of Health — but they still involve opioids.

The White House Council of Economic Advisers estimated this week that abuse of opioids cost the economy about $504 billion in 2015, or nearly three percent of that year’s overall economic output in the U.S. Those costs include health-care expenses, spending on criminal justice and first responders, and lost worker productivity.

“There’s currently a lot more costs of addiction that are being borne by society in a more diffuse way,” said Kosali Simon, a health economist at Indiana University.

Attempts to design opioids that can’t be easily abused have done little to alter the market, and pushed some people toward illicit drugs such as heroin and synthetic fentanyl. Purdue Pharma reformulated its OxyContin painkiller to resist being crushed or liquefied — and thus harder to snort or inject — in 2010. That was followed by a marked increase in U.S. heroin overdoses.

Other medications designed to thwart manipulation have had safety issues. In July, Endo International pulled its Opana ER from the market at the request of U.S. regulators, who said it helped worsen an outbreak of HIV among intravenous drug users.

Drug plans have been reluctant to pay for abuse-resistant pain medicines, which often cost more and can be more difficult to administer.

At the same time, payers are limiting patients’ access to older pain drugs. Cigna took OxyContin off its list of preferred drugs for 2018, though it still covers other opioids. CVS said its pharmacy-benefits management arm will limit prescriptions to a seven-day supply, and Express Scripts Holding Co. also said it would curb prescriptions.

That leaves patients with a difficult choice. Abuse-deterrent painkillers might cost as much as $250 out of pocket. But generic opioids cost as little as $2, according to Denis Patterson, a pain specialist in Reno, Nevada.

Abuse-resistant drugs get “denied 90 percent of the time. But the pain pills will get approved every single time,” said Patterson.

“Shouldn’t it be flipped,” he said, “in that the things which can get people better should have better coverage?”


Health Politics

FOLLOW US
Follow us on Twitter Follow us on Facebook Follow our RSS feed
Union Leader app for Apple iPad or Android *
Click to download from Apple Apps StoreClick to download from Android Marketplace
* e-Edition subscription required